Phathom Pharmaceuticals (PHAT) Payables (2018 - 2026)

Phathom Pharmaceuticals (PHAT) has reported Payables for 9 consecutive years, with $5.4 million the latest figure, recorded in Q2 2026.

• In Q2 2026, Payables rose 33.76% year-over-year to $5.4 million; the TTM figure through Jun 2026 stood at $5.4 million (up 33.76% YoY), while the FY2025 annual figure was $5.0 million, down 52.57% from the prior year.
• Payables eased to $5.4 million in Q2 2026 per PHAT's latest filing, from $6.4 million in the prior quarter.
• Across five years, Payables topped out at $12.6 million in Q4 2023 and bottomed at $1.1 million in Q3 2025.
• Historically, Payables has averaged $6.7 million across 5 years, with a median of $6.1 million in 2023.
• Annual changes were most pronounced in 2022 — Payables soared 94.12% — and 2025, when it tumbled 84.93%.
• Phathom Pharmaceuticals' Payables stood at $10.0 million in 2022, then gained by 26.05% to $12.6 million in 2023, then fell by 16.62% to $10.5 million in 2024, then plunged by 52.57% to $5.0 million in 2025, then advanced by 7.59% to $5.4 million in 2026.
• Business Quant data shows PHAT's Payables at $5.4 million in Q2 2026, $6.4 million in Q1 2026, and $5.0 million in Q4 2025.